论文部分内容阅读
目的:观察羟苯磺酸钙对慢性肾脏病(CKD)患者胱抑素C的影响,评价其延缓肾功能恶化进展的作用。方法:符合标准的患者73人随机分成两组,对照组39例予常规治疗,治疗组34例在常规治疗基础上加用羟苯磺酸钙500 mg,po tid。疗程8周。测定两组治疗前后血胱抑素C(CYS-C)、血清肌酐(Cr)和肾小球滤过率(GFR)等指标的变化。结果:治疗组治疗后CYS-C、Cr水平下降,GFR上升,与治疗前比较差异显著(P<0.05);与对照组治疗后比较,差异有统计学意义(P<0.05);对照组治疗后血Cr较治疗前下降(P<0.05),CYS-C、GFR与治疗前比较,差异无统计学意义。结论:羟苯磺酸钙可以降低CKD患者的CYS-C、Cr水平,改善GFR,进而延缓肾功能下降速度。
Objective: To observe the effect of calcium dobesilate on the cystatin C in patients with chronic kidney disease (CKD) and evaluate the role of calcium dobesilate in retarding the progression of renal dysfunction. Methods: 73 eligible patients were randomly divided into two groups. The control group, 39 patients were treated routinely. In the treatment group, 34 patients received 500 mg calcium dobesilate on the basis of routine treatment. Treatment for 8 weeks. The change of serum cystatin C (CYS-C), serum creatinine (Cr) and glomerular filtration rate (GFR) were measured before and after treatment. Results: After treatment, the levels of CYS-C and Cr were decreased and the GFR was increased in the treatment group compared with that before treatment (P <0.05); the difference was statistically significant (P <0.05) After the blood Cr decreased compared with before treatment (P <0.05), CYS-C, GFR compared with before treatment, the difference was not statistically significant. Conclusion: Calcium dobesilate can reduce the levels of CYS-C and Cr in patients with CKD, improve GFR, and then delay the decline of renal function.